MabThera

Phase 3Biologic

Pfizer

MabThera is one of 91 biologic programs targeting Chronic Lymphocytic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic LeukemiaActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Chronic Lymphocytic LeukemiaPreclinical

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

109 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

38 2

Rituxan

Oncovin

33 4

Polivy

Roche

Phase 3

20 5

Gemzar

Johnson & Johnson

Phase 3

18 6

Adriamycin

Pfizer

Phase 3

18 7

Gazyva

Roche

Phase 3

18 8

Oncovin

Eli Lilly

Phase 3

18 9

Cytoxan

BBaxter Healthcare Corporation

Rayos

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis9 trials

MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis

Withdrawn·MMabion SA·Phase 3·NCT04680962

A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action

Completed·MMedical University of Vienna·Phase 4·NCT01638715·115 enrolled

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01682512·294 enrolled

Show 6 more trials

Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis

Completed·—·Phase 1/2·NCT02296775·276 enrolled

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Completed· Pfizer logo

Pfizer·Phase 2·NCT01526057·220 enrolled

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

Completed·AArchigen Biotech Limited·Phase 1·NCT02819726·294 enrolled

Completed·CCelltrion·Phase 3·NCT02149121·384 enrolled

Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis

Active, not recruiting·MMabscale, LLC·Phase 1·NCT06175338·208 enrolled

A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis

Terminated·JJHL Biotech, Inc.·Phase 1·NCT03161457·153 enrolled

Follicular Lymphoma4 trials

Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01950273·95 enrolled

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Completed·AArchigen Biotech Limited·Phase 3·NCT02809053·315 enrolled

Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.

Withdrawn· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 3·NCT04671420

Show 1 more trial

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Completed· Pfizer logo

Pfizer·Phase 3·NCT02213263·394 enrolled

Renal Transplantation3 trials

Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation

Completed·UUniversity Hospital, Tours·Phase 3·NCT01350882·40 enrolled

Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation

Terminated·TTechnical University of Munich·Phase 2·NCT00568477·200 enrolled

Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation

Unknown status·UUniversity Hospital, Tours·Phase 3·NCT01066689·64 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting·GGWT-TUD GmbH·Phase 3·NCT04833114·306 enrolled

A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated·JJHL Biotech, Inc.·Phase 3·NCT03670901·8 enrolled

Chronic Lymphocytic Leukemia1 trial

An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

Completed· Roche logo

Roche··NCT03289182·701 enrolled

8 more indications

Tics1 trial

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT01390441·100 enrolled

Primary Sjögren's Syndrome1 trial

Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome

Completed·UUniversity of Copenhagen·Phase 2·NCT00426543·21 enrolled

Trial1 trial

Comparative Pharmacokinetic Trial of RGB-03 and MabThera

Unknown status·GGedeon Richter Plc.·Phase 1·NCT02371096

Pemphigus1 trial

Effect of Anti CD20 in Pemphigus Desease

Completed·UUniversity Hospital, Rouen·Phase 2/3·NCT00213512·22 enrolled

Refractory1 trial

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Completed· Novartis logo

Novartis·Phase 1/2·NCT01274182·312 enrolled

Drug1 trial

Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®

Terminated·BBiointegrator LLC·Phase 1·NCT03061838·8 enrolled

Lymphoma1 trial

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

Completed·MmAbxience Research S.L.·Phase 3·NCT02268045·272 enrolled

Bullous Pemphigoid1 trial

Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid

Completed·UUniversity Hospital, Rouen·Phase 3·NCT00525616·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for MabThera. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MabThera compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MabThera. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Pfizer

MabThera

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis9 trials

Follicular Lymphoma4 trials

Renal Transplantation3 trials

Diffuse Large B-Cell Lymphoma2 trials

Chronic Lymphocytic Leukemia1 trial

Tics1 trial

Primary Sjögren's Syndrome1 trial

Trial1 trial

Pemphigus1 trial

Refractory1 trial

Drug1 trial

Lymphoma1 trial

Bullous Pemphigoid1 trial

References

Drug Info

Quick Facts

Related News